Evofem Biosciences Q3 net sales rise

Reuters11-14

<a href="https://laohu8.com/S/EVFM">Evofem Biosciences</a> Q3 net sales rise

Overview

Evofem Q3 net sales rise 10% yr/yr to $5.0 mln
Company posts $1.0 mln operating income, reversing prior yr $2.4 mln loss
Operating expenses fall 42% yr/yr, aiding profit turnaround

Outlook

Company aims to reduce manufacturing costs by 50% for PHEXX and SOLOSEC
SOLOSEC submitted for marketing approval in the UAE
Company did not provide specific financial guidance for future periods

Result Drivers

SALES REBOUND - Sales increased 10% yr/yr due to strategic marketing and press coverage, per CEO Saundra Pelletier
COST REDUCTION - Co reduced manufacturing costs for PHEXX and SOLOSEC by 50%, facilitating entry into price-sensitive markets
OPERATING EXPENSES DROP - Operating expenses fell 42% yr/yr, driven by reduced general and administrative expenses and a one-time gain

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Sales		$4.95 mln
Q3 Net Income		-$1.57 mln
Q3 Income from Operations		$951,000
Q3 Operating Expenses		$4.001 mln
Q3 Pretax Profit		-$1.57 mln

Press Release: ID:nPn1gw3S9a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583661512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583661512","market":"us","top_or_hot":-1,"title":"Evofem Biosciences Q3 net sales rise","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title> <a href=\"https://laohu8.com/S/EVFM\">Evofem Biosciences</a> Q3 net sales rise</title></head><body><p><span>Overview</span></p><ul><li><p>Evofem Q3 net sales rise 10% yr/yr to $5.0 mln</p></li><li><p>Company posts $1.0 mln operating income, reversing prior yr $2.4 mln loss</p></li><li><p>Operating expenses fall 42% yr/yr, aiding profit turnaround</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company aims to reduce manufacturing costs by 50% for PHEXX and SOLOSEC</p></li><li><p>SOLOSEC submitted for marketing approval in the UAE</p></li><li><p>Company did not provide specific financial guidance for future periods</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SALES REBOUND - Sales increased 10% yr/yr due to strategic marketing and press coverage, per CEO Saundra Pelletier</p></li><li><p>COST REDUCTION - Co reduced manufacturing costs for PHEXX and SOLOSEC by 50%, facilitating entry into price-sensitive markets</p></li><li><p>OPERATING EXPENSES DROP - Operating expenses fell 42% yr/yr, driven by reduced general and administrative expenses and a one-time gain</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Sales</p></td><td></td><td><p>$4.95 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.57 mln</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>$951,000</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$4.001 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$1.57 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nPn1gw3S9a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evofem Biosciences Q3 net sales rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvofem Biosciences Q3 net sales rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title> <a href=\"https://laohu8.com/S/EVFM\">Evofem Biosciences</a> Q3 net sales rise</title></head><body><p><span>Overview</span></p><ul><li><p>Evofem Q3 net sales rise 10% yr/yr to $5.0 mln</p></li><li><p>Company posts $1.0 mln operating income, reversing prior yr $2.4 mln loss</p></li><li><p>Operating expenses fall 42% yr/yr, aiding profit turnaround</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company aims to reduce manufacturing costs by 50% for PHEXX and SOLOSEC</p></li><li><p>SOLOSEC submitted for marketing approval in the UAE</p></li><li><p>Company did not provide specific financial guidance for future periods</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SALES REBOUND - Sales increased 10% yr/yr due to strategic marketing and press coverage, per CEO Saundra Pelletier</p></li><li><p>COST REDUCTION - Co reduced manufacturing costs for PHEXX and SOLOSEC by 50%, facilitating entry into price-sensitive markets</p></li><li><p>OPERATING EXPENSES DROP - Operating expenses fell 42% yr/yr, driven by reduced general and administrative expenses and a one-time gain</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Sales</p></td><td></td><td><p>$4.95 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.57 mln</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>$951,000</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$4.001 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$1.57 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nPn1gw3S9a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP17R:1","article_id":"2583661512","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583661512","pubTimestamp":1763069024,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evofem Biosciences Q3 net sales riseOverviewEvofem Q3 net sales rise 10% yr/yr to $5.0 mlnCompany posts $1.0 mln operating income, reversing prior yr $2.4 mln lossOperating expenses fall 42% yr/yr, ai","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4007":"制药","EVFM":"Evofem Biosciences, Inc."},"translate_title":"Evofem Biosciences第三季度净销售额增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVFM":0.9},"content_text":"Evofem Biosciences Q3 net sales riseOverviewEvofem Q3 net sales rise 10% yr/yr to $5.0 mlnCompany posts $1.0 mln operating income, reversing prior yr $2.4 mln lossOperating expenses fall 42% yr/yr, aiding profit turnaroundOutlookCompany aims to reduce manufacturing costs by 50% for PHEXX and SOLOSECSOLOSEC submitted for marketing approval in the UAECompany did not provide specific financial guidance for future periodsResult DriversSALES REBOUND - Sales increased 10% yr/yr due to strategic marketing and press coverage, per CEO Saundra PelletierCOST REDUCTION - Co reduced manufacturing costs for PHEXX and SOLOSEC by 50%, facilitating entry into price-sensitive marketsOPERATING EXPENSES DROP - Operating expenses fell 42% yr/yr, driven by reduced general and administrative expenses and a one-time gainKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Sales$4.95 mlnQ3 Net Income-$1.57 mlnQ3 Income from Operations$951,000Q3 Operating Expenses$4.001 mlnQ3 Pretax Profit-$1.57 mlnPress Release: ID:nPn1gw3S9aFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583661512","isCrawlerRequest":true}